Economics of Nephroprotection in Arterial Hypertension and Type 2 Diabetes Mellitus

被引：0
|
作者：
Belousov, Yu B. [1 ]
Shestakova, M. V. [1 ]
Belousov, D. Yu [1 ]
机构：
[1] Russian State Med Univ, Moscow 117437, Russia
来源：
KARDIOLOGIYA | 2008年 / 48卷 / 12期
关键词：
arterial hypertension; diabetes mellitus type 2; sartans; microalbuminuria; economic efficacy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Based on results of large-scale controlled trials of irbesartan (1), valsartan (V) and amlodipine (A) (PRIME and MARVAL) we carried out the Markov's modeling of their pharmacoeconomic parameters in arterial hypertension (AH) combined with diabetes mellitus type 2 (DM 2) and microalbuminuria (MAU) projected for 8-years perspective. Cost and efficacy was evaluated taking into account years of life gained and outcomes of concomitant diseases and complications. Indexes of cost/efficacy (C/E) were calculated for each drug. Among investigated drugs I appeared to be the most economic at the account of retardation of development of terminal nephropathy and cardiovascular diseases. The use of I compared with V could save 565300 rub/100 patients/year. C/E of I was 26.5 and 37.4% lower that those of V and A, respectively. Costs of year of life saved was 12716,16432, and 18325 for 1, V, and A, respectively. Comparative pharmacoeconomic modeling of 8-year economic perspectives of 1, V and A demonstrated financial benefits of 1.
引用
收藏
页码：14 / 19
页数：6
相关论文
共 50 条
  • [1] On pathogenesis of arterial hypertension in type 2 diabetes mellitus
    Volkov, V. S.
    Rudenko, E. V.
    Rokkina, S. A.
    Poselyugina, O. B.
    [J]. DIABETES MELLITUS, 2011, 14 (02): : 53 - 55
  • [2] MICROALBUMINURIA, ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
    Hoxha, V.
    Petrela, E.
    Zaimi, E.
    Hasani, E.
    Laci, I.
    Cela, L.
    [J]. JOURNAL OF HYPERTENSION, 2010, 28 : E290 - E290
  • [3] DURATION OF DIABETES MELLITUS IS ASSOCIATED WITH INCREASED ARTERIAL STIFFNESS IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
    Starostina, E.
    Troitskaya, E.
    Kobalava, Z.
    [J]. JOURNAL OF HYPERTENSION, 2017, 35 : E39 - E40
  • [4] Arterial hypertension and type 1 diabetes mellitus
    Uruski, Pawel
    Uruska, Aleksandra
    Zozulinska, Dorota
    Tykarski, Andrzej
    [J]. ARTERIAL HYPERTENSION, 2007, 11 (02): : 85 - 94
  • [5] Nephroprotection in diabetes mellitus
    Singh, NK
    [J]. CLINICAL AND EXPERIMENTAL HYPERTENSION, 1999, 21 (1-2) : 85 - 94
  • [6] Nephroprotection Diabetes Mellitus Type 2: Lessons From the ADVANCE trial
    Nedogoda, S. V.
    [J]. KARDIOLOGIYA, 2011, 51 (12) : 57 - 59
  • [7] Glimepiride in patients with arterial hypertension, obesity and type 2 diabetes mellitus
    Mychka, V
    Gornostaev, V
    Bogieva, R
    Chazova, I
    [J]. JOURNAL OF HYPERTENSION, 2003, 21 : S330 - S330
  • [8] Clinical Implications in Arterial Hypertension and Type-2 Diabetes Mellitus
    Domenech, Monica
    Coca, Antonio
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2008, : 56E - 62E
  • [9] Therapeutic compliance in patients with arterial hypertension and type 2 diabetes mellitus
    Gutierrez-Angulo, M. L.
    Lopetegi-Uranga, P.
    Sanchez-Martin, I.
    Garaigordobil-Landazabal, M.
    [J]. REVISTA DE CALIDAD ASISTENCIAL, 2012, 27 (02) : 72 - 77
  • [10] Diabetes mellitus type 2, arterial hypertension and the risk of cardiovascular complications
    Kislyak, O. A.
    Myshlyaeva, T. O.
    Malysheva, N., V
    [J]. DIABETES MELLITUS, 2008, 11 (01): : 45 - 49
12345